NTLA Insider Trading Activity and SEC Form 4 Filings
NTLA insider trading summary
Over the past 12 months, insiders at Intellia Therapeutics, Inc. (NTLA) reported 19 sales worth $2.3M by 7 insiders and 1 open-market purchase worth $1.4M by 1 insider on SEC Form 4. Net insider selling was $869K.
Latest NTLA insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Nov 2, 2026 | John M Leonard | President and CEO | Sell | $108K (9,000 @ $11.99) |
| Oct 2, 2026 | Michael P Dube | VP, Chief Accounting Officer | Sell | $23K (1,864 @ $12.43) |
| Aug 21, 2026 | John M Leonard | President and CEO | Sell | $36K (2,785 @ $13.00) |
| Aug 20, 2026 | John M Leonard | President and CEO | Sell | $251K (19,890 @ $12.60) |
| Jul 22, 2026 | Edward J Dulac III | EVP, Chief Financial Officer | Sell | $91K (8,111 @ $11.25) |
| Jul 2, 2026 | Edward J Dulac III | EVP, Chief Financial Officer | Sell | $84K (4,677 @ $18.00) |
| Jul 1, 2026 | Michael P Dube | VP, Chief Accounting Officer | Sell | $44K (2,641 @ $16.78) |
| Mar 2, 2026 | James Basta | EVP, General Counsel | Sell | $17K (1,211 @ $13.78) |
| Mar 2, 2026 | Eliana Clark | EVP, Chief Technical Officer | Sell | $8K (607 @ $13.78) |
| Jan 5, 2026 | Michael P Dube | VP, Chief Accounting Officer | Sell | $28K (2,989 @ $9.21) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.